2017
Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom
Alasil T, Munoz N, Keane PA, Tufail A, Coady PA, Novais E, de Carlo TE, Baumal CR, Waheed NK, Duker JS, Adelman RA. Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom. International Journal Of Retina And Vitreous 2017, 3: 9. PMID: 28428893, PMCID: PMC5392942, DOI: 10.1186/s40942-017-0060-4.Peer-Reviewed Original ResearchPolypoidal choroidal vasculopathyFinal visual acuityWorse visual outcomeVisual acuityBilateral diseaseVisual outcomeTertiary centerFemale predominanceChoroidal vasculopathyDiagnosis of PCVInitial visual acuityRacial variationMulticenter retrospective studyLength of followDifferent treatment modalitiesSignificant decreaseIndocyanine green angiography imagesLens statusPCV patientsVision gainInitial presentationRetrospective studyWorse visionPolypoidal lesionsTreatment modalities
2012
Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy?
Prescott CR, Sklar CA, Lesser RL, Adelman RA. Is Intravitreal Bevacizumab an Effective Treatment Option for Nonarteritic Anterior Ischemic Optic Neuropathy? Journal Of Neuro-Ophthalmology 2012, 32: 51-53. PMID: 22269947, DOI: 10.1097/wno.0b013e318240596e.Peer-Reviewed Original ResearchConceptsNonarteritic anterior ischemic optic neuropathyAnterior ischemic optic neuropathyIschemic optic neuropathyVisual acuityIntravitreal bevacizumabOptic neuropathyTreatment optionsIntravitreal bevacizumab injectionEffective treatment optionVisual field defectsBevacizumab injectionFellow eyesClinical outcomesRetrospective studyTreatment modalitiesNatural courseField defectsPatientsDecreased acuitySmall seriesAcuityBevacizumabProfound lossVisual fieldNeuropathy